enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Prescient Therapeutics - Wikipedia

    en.wikipedia.org/wiki/Prescient_Therapeutics

    Prescient Therapeutics Ltd (Prescient) was created in 2014 by bringing together two small molecule drug assets from separate US private companies (Pathway Oncology for PTX-100 and AKTivate Therapeutics for PTX-200) into the existing ASX-listed shell company Virax Holdings Ltd (Virax).

  3. Juno Therapeutics - Wikipedia

    en.wikipedia.org/wiki/Juno_Therapeutics

    In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. [6] Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. [7]

  4. Kite Pharma - Wikipedia

    en.wikipedia.org/wiki/Kite_Pharma

    Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells.

  5. 10 Best Hydrogen Fuel Cell Stocks To Buy Now - AOL

    www.aol.com/news/10-best-hydrogen-fuel-cell...

    8. Nikola Corporation (NASDAQ: NKLA)NKLA ranks 8th in our list of the best hydrogen fuel cell stocks to buy now. Nikola is one of the world’s most famous electric car technology companies.

  6. Cellectis - Wikipedia

    en.wikipedia.org/wiki/Cellectis

    Cellectis became a publicly traded company in 2007, and raised €21.2 million in a stock offering on Euronext. In 2010, it acquired Cyto Pulse, which had developed a new electroporation technology, [ 3 ] and in 2011 it paid €28 million for Cellartis, a Swedish biotechnology company. [ 2 ]

  7. CAR T cell - Wikipedia

    en.wikipedia.org/wiki/CAR_T_cell

    A first generation CAR containing a CD4 extracellular domain and a CD3ζ intracellular domain was used in the first clinical trial of chimeric antigen receptor T cells by the biotechnology company Cell Genesys in the mid 1990s, allowing adoptively transferred T cells to target HIV infected cells, although it failed to show any clinical ...

  8. Oxford Biomedica - Wikipedia

    en.wikipedia.org/wiki/Oxford_BioMedica

    In December 2019, the company announced that it has extended its commercial supply agreement with Novartis for the manufacture of lentiviral vectors for the Novartis CAR-T portfolio including five lentiviral vectors for CAR-T products, which builds on the existing three-year commercial supply agreement signed by the parties in July 2017. [9]

  9. Mustang Bio - Wikipedia

    en.wikipedia.org/wiki/Mustang_Bio

    Mustang Bio was founded in 2015 and in the same year became a partner company of Fortress Biotech. [5] [7] In April 2017, Manuel Litchman took over as CEO of Mustang Bio, and in October of the same year, the company signed a lease with the University of Massachusetts Medicine Science Park in Worcester, MA, for a manufacturing facility to support the clinical development and commercialization ...